Researchers discovered a new Gene Therapy for muscular dystrophy
The protein dystrophin, absent in people with muscular dystrophy, will subsequently begin to be produced by the additional genetic code.
Editor's Desk
New subtypes of Parkinson’s Disease can be defined by Machine Learning
The different patterns of illness development that the subtypes exhibited allowed the investigators to identify them.
Research: A new neural biomarker for OCD
Two to three per cent of people worldwide suffer from OCD, a prevalent and debilitating mental illness. OCD affects over two million people in the United States.
E. faecalis biofilms are targeted by a phage-derived enzyme to reduce acute Graft-Versus-Host Disease
Recently, Japanese researchers discovered endolysin, an enzyme generated from bacteriophages that may attack Enterococcus faecalis biofilms. Their results provide promise for customized allo-HCT therapies.
Cystic Fibrosis mutation in human lung cells corrected by Prime Editing
Researchers at the University of Iowa, the Broad Institute of MIT, Harvard, and Harvard have now created a gene-editing method that effectively fixes the most prevalent mutation affecting 85% of patients
New research suggests an improved method for the detection of thyroid cancer
The study investigated if cancer status differed according to individuals’ RAS genetic variations.
Discovery of new T cells and genes related to immune disorders
They discovered many subsets of uncommon T cell types, making up less than 5% of the total, after examining almost a million human T cells.
In a young kid, gene therapy halts the advancement of a rare hereditary disease
Delivering a healthy copy of a gene to a person whose gene(s) are malfunctioning is known as gene therapy.
Phosphate findings in NASA’s OSIRIS-REx samples
Bennu is home to the primordial materials that gave rise to our solar system, according to the OSIRIS-REx Sample Analysis Team.
Advancement in research improves checkpoint inhibitor therapy for cancer
Researchers at Scripps Research have recently discovered that when taken with checkpoint inhibitors, the immunosuppressive medication ruxolitinib, which is licenced, enhanced T-cell responses and increased the drugs’ ability to fight cancer.
